Increased thrombogenicity is associated with revascularization outcomes in patients with chronic limb-threatening
Naoto Kuyama1, Koichi Kaikita2, Masanobu Ishii1
1Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Insights
The atheroma chip test (AR10-AUC30) can predict revascularization after endovascular therapy in chronic limb-threatening ischemia (CLTI) patients. This suggests hypercoagulability contributes to CLTI progression, potentially benefiting from anticoagulant therapy.
Area of Science:
- Vascular Medicine
- Thrombosis Research
- Interventional Cardiology
Background:
- Clinically driven target lesion revascularization (CD-TLR) is common after endovascular therapy (EVT) for chronic limb-threatening ischemia (CLTI).
- Quantitative thrombogenicity assessment using the total thrombus-formation analysis system (T-TAS) may predict CD-TLR.
- Understanding T-TAS parameters' association with CD-TLR is crucial for optimizing CLTI management.
Purpose of the Study:
- To investigate the association between T-TAS parameters and CD-TLR in patients undergoing EVT.
- To determine if T-TAS can predict the need for revascularization in CLTI patients post-EVT.
- To explore the role of hypercoagulability in CLTI progression and its impact on revascularization outcomes.
Main Methods:
- Analysis of 34 CLTI patients and 62 non-CLTI patients who underwent EVT.
- Measurement of platelet chip (PL24-AUC10) and atheroma chip (AR10-AUC30) parameters using T-TAS.
- Clinical follow-up to assess CD-TLR, with statistical analysis including multivariable Cox regression and ROC curve analysis.
Main Results:
- In CLTI patients, higher AR10-AUC30 was significantly associated with CD-TLR (P=.01).
- AR10-AUC30 independently predicted CD-TLR in CLTI patients (HR, 2.04; P=.01).
- An AR10-AUC30 cutoff of 1646 predicted CD-TLR with high sensitivity (0.93) and AUC (0.85).
Conclusions:
- The AR10-AUC30 parameter from T-TAS shows potential for predicting CD-TLR in CLTI patients.
- Hypercoagulability may play a significant role in CLTI progression.
- Anticoagulant therapy could be beneficial in preventing revascularization in CLTI patients.
Objectives:
Clinically driven target lesion revascularization (CD-TLR) frequently occurs after endovascular therapy (EVT) in patients with chronic limb-threatening ischemia (CLTI). The total thrombus-formation analysis system (T-TAS) can quantitatively evaluate thrombogenicity. Therefore, we aimed to elucidate the association of the T-TAS parameters with CD-TLR.
Methods:
We analyzed 34 patients with CLTI and 62 patients without CLTI who had undergone EVT. Blood samples collected on the day of EVT were used in the T-TAS to compute the thrombus formation area under the curve for the first 10 minutes for the platelet chip tested at a flow rate of 24 μL/min (PL24-AUC10) and area under the curve for the first 30 minutes for the atheroma chip tested at a flow rate of 10 μL/min (AR10-AUC30). After EVT, clinical follow-up was performed, and the presence of CD-TLR was assessed.
Results:
During the follow-up period (median, 574 days), 10 patients (29%) in the CLTI group and 11 (18%) in the non-CLTI group had required CD-TLR. In the CLTI group, the patients with CD-TLR had had a higher AR10-AUC30 vs those without (median, 1694 [interquartile range, 1657-1799] vs median, 1561 [interquartile range, 1412-1697]; P = .01). In contrast, the PL24-AUC10 showed no significant differences when stratified by CD-TLR in either group. For the CLTI patients, multivariable Cox regression analysis using propensity score matching revealed that the AR10-AUC30 was an independent predictor of CD-TLR even after adjusting for baseline demographics, lesion characteristics, and anticoagulant use (hazard ratio, 2.04; 95% confidence interval, 1.18-3.88; P = .01; per 100-unit increase). In contrast, for those without CLTI, neither the AR10-AUC30 nor the PL24-AUC10 was significantly associated with CD-TLR. Receiver operating characteristics curve analysis identified an AR10-AUC30 level of 1646 as an optimal cutoff value to predict for CD-TLR (AUC, 0.85; sensitivity, 0.93; specificity, 0.56).
Conclusions:
For patients with CLTI, but not for those without CLTI, the AR10-AUC30 showed potential to predict for CD-TLR. This finding suggests that hypercoagulability might play a predominant role in the progression of CLTI and that anticoagulant therapy might be useful in preventing revascularization.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
08:16High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model
Published on: March 16, 2022
Related Concept Videos
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
